Recommendations for treatment algorithm of HFrEF
Video navigation menu
Benefits of combinations of recommended therapies in HFrEF 02:27
The majority of patients with HF are not on target dose 04:54
Limitations of the current guideline 07:04
Recommendations for the treatment of HFrEF 09:54
Educational information
This presentation was broadcasted at the e-SPACE CRM conference, a global web-conference on the cardio-renal-metabolic syndrome, that was held January 22-24, 2021.
Faculty
Andrew Coats, MD is Academic Vice-President at University of Warwick, Coventry, UK and Monash University, Melbourne, Australia. He is also president of the Heart Failure Association of the ESC.
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: